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Background. Drug-resistant tuberculous meningitis (TBM) is difficult to diagnose and treat. Mortality is high and optimal 
treatment is unknown. We compared clinical outcomes of drug-resistant and -susceptible TBM treated with either standard or 
intensified antituberculosis treatment.
Methods. We analyzed the influence of Mycobacterium tuberculosis drug resistance on the outcomes of patients with TBM 
enrolled into a randomized controlled trial comparing a standard, 9-month antituberculosis regimen (containing rifampicin 10 mg/
kg/day) with an intensified regimen with higher-dose rifampicin (15 mg/kg/day) and levofloxacin (20 mg/kg/day) for the first 8 
weeks. The primary endpoint of the trial was 9-month survival. In this subgroup analysis, resistance categories were predefined as 
multidrug resistant (MDR), isoniazid resistant, rifampicin susceptible (INH-R), and susceptible to rifampicin and isoniazid (INH-S 
+ RIF-S). Outcome by resistance categories and response to intensified treatment were compared and estimated by Cox regression.
Results. Of 817 randomized patients, 322 had a known drug resistance profile. INH-R was found in 86 (26.7%) patients, MDR in 
15 (4.7%) patients, rifampicin monoresistance in 1 patient (0.3%), and INH-S + RIF-S in 220 (68.3%) patients. Multivariable regres-
sion showed that MDR (hazard ratio [HR], 5.91 [95% confidence interval {CI}, 3.00–11.6]), P < .001), was an independent predictor 
of death. INH-R had a significant association with the combined outcome of new neurological events or death (HR, 1.58 [95% CI, 
1.11–2.23]). Adjusted Cox regression, corrected for treatment adjustments, showed that intensified treatment was significantly asso-
ciated with improved survival (HR, 0.34 [95% CI, .15–.76], P = .01) in INH-R TBM.
Conclusions. Early intensified treatment improved survival in patients with INH-R TBM. Targeted regimens for drug-resistant 
TBM should be further explored.
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Tuberculous meningitis (TBM) is the most fatal form of tuber-
culosis (TB), killing approximately one-third of patients despite 
antituberculosis treatment [1–4]. Reports on drug-resistant 
TBM are limited due to the rarity of the disease and the dif-
ficulty of isolating mycobacteria from the cerebrospinal fluid 
(CSF), but resistance prevalence is broadly consistent with 
background Mycobacterium tuberculosis resistance rates [5–8]. 
The optimal treatment of drug-resistant TBM is unknown.
Isoniazid and rifampicin are the principal drugs in TBM 
treatment, given throughout the regimen. Isoniazid pene-
trates the blood–brain barrier effectively and has the highest 
early bactericidal activity (EBA) of all first-line drugs, killing 
approximately 95% of mycobacteria in the first 2  days [9]. 
Despite low penetration into the CSF, rifampicin is thought 
to be highly active in the days thereafter, against both divid-
ing and persistent mycobacteria. The complementary role of 
isoniazid and rifampicin is illustrated by the high mortality 
of patients with confirmed multidrug-resistant (MDR) TBM, 
which approaches 100% when treated with standard first-line 
regimens and as low as 40% when second-line regimens are 
used [8, 10]. Isoniazid resistance has also been associated with 
mortality in TBM. In US patients, isoniazid-resistant TBM was 
associated with death (odds ratio, 2.07 [95% confidence interval 
{CI}, 1.30–3.29]) regardless of human immunodeficiency virus 
(HIV) status [11]. In Vietnam, isoniazid-resistant TBM was 
associated with higher mortality (adjusted hazard ratio [HR], 
1.78 [95% CI, 1.18–2.66]) in HIV-infected subjects, but not in 
HIV-uninfected subjects [8, 12].
In a 1:1 randomized double-blind trial, we investigated 
whether intensified treatment with higher-dose rifampicin and 
levofloxacin would benefit patients with TBM [13]. Although 
the trial did not show an overall benefit of intensified treatment, 
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the results suggested reduced mortality in isoniazid-resistant 
infection (HR, 0.45 [95% CI, .20–1.02], P =  .06) [14]. Higher 
doses of rifampicin are associated with higher EBA [15] and 
may lead to improved intracranial drug exposure [16, 17]. 
Fluoroquinolones have antituberculosis activity comparable to 
that of isoniazid [18]. Levofloxacin penetration in the CSF is 
good, with levels of 70% of plasma levels [19]. In isoniazid-re-
sistant TBM, the addition of these agents to the first-line reg-
imen may substitute for the loss of isoniazid early bacterial 
killing. In our trial, intensified treatment was initiated at the 
onset of treatment regardless of the drug resistance profile of 
the mycobacteria. This subgroup analysis describes the effect of 
intensified treatment on outcome in drug-resistant TBM.
METHODS
Study Design and Participants
Patients were recruited from 2 tertiary referral hospitals in Ho 
Chi Minh City, Vietnam. The full protocol and primary results 
are published elsewhere [13, 14]. In short, adults with a clinical 
diagnosis of TBM were eligible to enter. Exclusion criteria were a 
positive CSF Gram stain or India ink stain; known or suspected 
pregnancy; laboratory contraindications to antituberculosis 
therapy; MDR TBM diagnosed prior to enrollment; and lack of 
consent. Written informed consent to participate was obtained 
from all patients or their relatives. The trial was approved by the 
Oxford Tropical Research Ethics Committee and the institutional 
review boards of the Hospital for Tropical Diseases and Pham 
Ngoc Thach Hospital and the Ministry of Health, Vietnam.
Treatment
Patients were randomized to receive standard treatment or 
intensified treatment. Standard treatment consisted of isonia-
zid (5  mg/kg/day), rifampicin (10  mg/kg/day), pyrazinamide 
(25 mg/kg/day) and ethambutol (20 mg/kg/day) or streptomy-
cin (20 mg/kg/day) for 3 months, followed by rifampicin and 
isoniazid at the same doses for 6  months. Those previously 
treated for tuberculosis received additional streptomycin or eth-
ambutol for the first 3 months. Intensified treatment consisted 
of the standard regimen with an additional, weight-based dose 
of rifampicin (5 mg/kg/day) to achieve a total dose of 15 mg/
kg/day, and levofloxacin (20  mg/kg/day) for the first 8 weeks 
of treatment. For patients infected with M. tuberculosis resist-
ant to rifampicin and/or isoniazid on drug susceptibility testing 
(DST), treatment was adjusted at the discretion of the treating 
clinician, guided by the organism susceptibility. In general, iso-
niazid resistance was treated with a fluoroquinolone (levofloxa-
cin 750 mg and, in 1 case, moxifloxacin 400 mg until treatment 
end); occasionally an aminoglycoside (kanamycin 20  mg/kg/
day for 3 months) was used early in treatment. However, treat-
ment adjustment was not uniform across centers, as the opti-
mal regimens are not known. Consequently, a subset received 
additional treatment with at least a fluoroquinolone, regardless 
of randomized allocation, but treatment was not adjusted in all 
patients. Patients found to have rifampicin-resistant infection 
were treated with second-line drugs (a fluoroquinolone and an 
injectable agent, plus at least 3 other active drugs). All patients 
received adjunctive dexamethasone for the first 6–8 weeks as 
previously described [1]. HIV-infected patients received antiret-
roviral treatment according to Vietnamese guidelines [20].
Assessment of Outcome
The primary outcome was death during 9-month follow-up. 
Patients were monitored for drug toxicity, neurological deterio-
ration, and other clinical parameters. A secondary outcome was 
time to first new neurological event or death. New neurological 
events were defined as occurrence of any of the following adverse 
events after enrollment: cerebellar symptoms; coma/conscious-
ness deterioration or a fall in Glasgow Coma Scale score by ≥2 
points for ≥2 days from the highest previously recorded; cranial 
nerve palsy; hemiplegia, paraplegia, tetraplegia, or monoplegia; 
neurological deterioration requiring ventilation; seizures; or cer-
ebral herniation. Disability was also assessed as a secondary out-
come based on the 2 simple questions and the modified Rankin 
score and classified as good outcome, intermediate outcome, 
severe disability, or death, as previously described [1, 3, 20].
Investigations
Patients underwent lumbar puncture at baseline. CSF sam-
ples were centrifuged at 4000g for 15 minutes. Supernatant was 
removed to leave a 0.5-mL deposit, which was Ziehl-Neelsen 
stained, Xpert MTB/RIF (Cepheid) tested, and cultured by Bactec 
MGIT (Becton Dickinson) [21]. All positive cultures were tested 
for drug susceptibility to rifampicin, isoniazid, streptomycin, and 
ethambutol using a Bactec MGIT SIRE kit (Becton Dickinson) 
following manufacturer’s instructions, which contained the fol-
lowing critical concentrations: streptomycin 1.0 µg/mL, isoniazid 
0.1 µg/mL, rifampicin 1.0 µg/mL, and ethambutol 5.0 µg/mL.
Resistance Categories
Resistance was categorized based on the results of MGIT DST 
performed against rifampicin, isoniazid, on baseline samples 
(defined as sample taken any time in between 7 days prior to, or 
3 days after enrollment) of CSF, but also sputum, gastric fluid, 
or blood. The following categories were defined:
• MDR: resistance against both isoniazid and rifampicin. 
• Rifampicin resistant (RIF-R): resistance against rifampicin, 
susceptible to isoniazid. 
• Isoniazid resistant (INH-R): resistance against isoniazid, sus-
ceptible to rifampicin.
• No isoniazid or rifampicin resistance (INH-S + RIF-S): no 
resistance to isoniazid or rifampicin. 
In all categories, resistance to streptomycin and/or ethambu-
tol may be present.
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Statistical Analysis
Baseline characteristics for each of the resistance categories 
were summarized as median (interquartile range [IQR]) for 
continuous data and number (percentage) for categorical data. 
Clinical variables associated with specified resistance categories 
were assessed by univariate analysis. The Kruskal-Wallis test 
was used to compare continuous parameters and Fisher exact 
test for comparisons between categorical parameters. Kaplan-
Meier estimates were used to display survival of patients in the 
defined resistance categories, by randomized treatment arm. 
Overall survival and the time to the first new neurological event 
or death were modeled using Cox regression with resistance 
categories as the main covariate and additional adjustment 
for the randomized treatment arm, TBM severity grade, and 
HIV status. The ordinal disability outcome was modeled using 
a proportional odds logistical regression model and the same 
covariates. The effect of intensified treatment on survival in the 
INH-R group was modeled with a Cox regression model strati-
fied by TBM severity grade and HIV status in accordance with 
the primary trial publication [14]. To dissect the impact of later 
treatment alterations with fluoroquinolones in INH-R sub-
jects, “fluoroquinolone use” was assigned as a time-dependent 
covariate (ie, the start day of fluoroquinolone use was defined 
as study day 1 (baseline) in subjects randomized to intensi-
fied treatment, or the study day corresponding to the start of 
fluoroquinolone administration if it was initiated in the control 
arm) in an additional Cox regression model, stratified by TBM 
severity grade and HIV status. This means that fluoroquinolone 
usage was modeled to only affect the hazard (ie, the rate) of 
death from the time-point when fluoroquinolone treatment 
was actually started onward.
All statistical analyses were performed using the statistical 
software R version 3.0.2.
RESULTS
Baseline Characteristics
A total of 817 patients were randomized from April 2011 to June 
2014. Of those, 322 had DST results for baseline samples: 86 
(26.7%) were classified as INH-R, 15 (4.7%) patients as MDR, 
1 (0.3%) patient as RIF-R, and 220 (86.3%) patients as sensitive 
to both drugs. Only 176 (54.7%) patients had fully susceptible 
infection (Figure 1). Coinfection with HIV was found in 185 
(57.5%) patients. Patients in the different resistance categories 
had a similar clinical presentation, although patients infected 
with INH-R or MDR were more likely to report a previous epi-
sode of TB infection (P < .001). In particular, British Medical 
Research Council (MRC) grade on presentation and chest radi-
ographic findings were similar between groups, and CSF results 
were also broadly similar. Although not statistically significant, 
Figure 1. Study flow diagram. *Nine patients who had isoniazid resistance detected and were randomized to intensified treatment received treatment adjustment with the 
addition of at least a fluoroquinolone. †Fifteen patients who had isoniazid resistance detected and were randomized to standard treatment received treatment adjustment 
with the addition of at least a fluoroquinolone. ‡Four patients who had rifampicin resistance detected and were randomized to intensified treatment received treatment 
adjustment with at least a fluoroquinolone. For 3 patients, this was part of a second-line treatment schedule and 1 patient received levofloxacin and amikacin added to first-
line drugs. §Two patients who had rifampicin resistance detected and were randomized to standard treatment received treatment adjustment with at least a fluoroquinolone. 
One patient with rifampicin monoresistance received this as part of second-line therapy. The other patient had multidrug resistance and received only additional levofloxacin 
and no other second-line agents. Abbreviations: CSF, cerebrospinal fluid; EMB, ethambutol; FQN, fluoroquinolone; INH,  isoniazid; mono, monoresistance; RIF,  rifampicin; 
STR, streptomycin.
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a higher proportion of patients with MDR were HIV infected 
(13/16 [81.3%]) (Table 1).
Time to Diagnosis of Drug Resistance and Relevant Treatment Adjustment 
With Fluoroquinolones
The median time to diagnosis of INH-R in the 86 INH-resistant 
patients was 70  days (IQR, 48–83  days). When drug resist-
ance was detected prior to 56 days, the study intervention was 
stopped (without unblinding of the allocation), if treatment 
adjustments were made. Among the 41 subjects in the stand-
ard-of-care arm, 15 subsequently had their treatment adjusted, 
by adding (at least) a fluoroquinolone (levofloxacin, n  =  14; 
moxifloxacin, n = 1) after a median time to initiation of 76 days 
(IQR, 61–92 days). In the intensified treatment arm (n = 45), 9 
INH-R patients received additional fluoroquinolone treatment 
(levofloxacin), with a median time to treatment adjustment 
of 105 days (IQR, 66–113 days) (Figure 1). Characteristics for 
patients receiving adjustment of treatment and those who did 
not are given in Supplementary Table 1.
Characteristics, outcome, and drug management of patients 
with MDR TBM are given in Supplementary Table  2. One 
patient had RIF-R (detected by Xpert MTB/RIF) and received 
Table 1. Baseline Characteristics
Characteristic
No or Other Resistance 
(n = 220)
INH Resistant  
(n = 86)
RIF Resistant or MDR 
(n = 16)
All Patients  
(n = 322) P Valuea
No. of patients 220/322 (68.3) 86/322 (26.7) 16/322 (5.0) 322/322 (100)
Age, y, median (IQR) 220 34 (29–41) 86 34 (29–41) 16 34 (31–41) 322 34 (29–41) .84
Male sex 220 156 (70.9) 86 61 (70.9) 16 14 (87.5) 322 231 (71.7) .42
Weight, kg, median (IQR) 220 47.7 (43.0–52.0) 86 48.0 (42.1–50.0) 16 50.0 (42.8–52.0) 322 48.0 (43.0–51.0) .54
Duration of illness, d, median (IQR) 220 15.0 (10.0–30.0) 86 15.0 (10.0–29.5) 16 25.0 (10.3–30.0) 322 15.0 (10.0–30.0) .68
Previous episode of TB 220 33 (15.0) 86 25 (29.1) 16 8 (50.0) 322 66 (20.5) <.001
HIV infected 220 125 (56.8) 86 47 (54.7) 16 13 (81.3) 322 185 (57.5) .13
Cranial nerve palsy 220 52 (23.6) 86 23 (26.7) 16 2 (12.5) 322 77 (23.9) .51
Hemiplegia 220 31 (14.1) 86 19 (22.1) 16 3 (18.8) 322 53 (16.5) .23
Paraplegia 220 7 (3.2) 86 9 (10.5) 16 0 (0) 322 16 (5.0) .03
Quadriplegia 220 4 (1.8) 86 1 (1.2) 16 0 (0) 322 5 (1.6) 1.00
GCS score, median (IQR) 220 14 (11–15) 86 15 (11–15) 16 15 (13–15) 322 14 (11–15) .40
MRC gradeb 220 86 16 322 .41
 1 87 (39.5) 29 (33.7) 8 (50.0)
 2 83 (37.7) 39 (45.3) 7 (43.8)
 3 50 (22.7) 18 (20.9) 1 (6.2)
Serum sodium level, mmol/L, 
median (IQR)
205 126.0 (122.0–131.0) 81 125.0 
(121.0–130.0)
16 125.5 
(121.0–128.0)
302 126.0 
(122.0–131)
.16
Chest radiograph 220 85 16 321 .75
 Consistent with TB 124 (56.4) 45 (52.9) 9 (56.3) 178 (55.5)
 Miliary TB 51 (23.2) 16 (18.8) 3 (18.8) 70 (21.8)
 Abnormal other 21 (9.6) 12 (14.1) 1 (6.3) 34 (10.6)
 Normal 24 (10.9) 12 (14.1) 3 (18.8) 39 (12.2)
CSF results
 WBC count, cells/µL, median (IQR) 216 199.5 (72.8–386) 86 108.5 
(32.3–316)
16 253.5 
(64.3–340.0)
318 180.0 
(58.0–382)
.06
 Lymphocytes, %, median (IQR) 210 74.5 (40.0–90.0) 84 86.0 
(53.5–100.0)
15 80.0 (34.0–95.0) 309 78.0 (44.0–95.0) .04
 Protein level, g/L, median (IQR) 211 1.48 (1.02–2.38) 82 1.24 (0.81–1.87) 16 1.28 (0.74–2.38) 309 1.41 (0.90–2.30) .15
 Lactate, mmol/L, median (IQR) 199 5.93 (4.50–7.69) 78 5.20 (4.40–6.84) 15 5.50 (4.81–7.30) 292 5.80 (4.49–7.40) .15
 Glucose, mmol/L, median (IQR) 212 1.49 (0.98–2.00) 81 1.58 (1.04–2.11) 16 1.60 (0.95–2.28) 309 1.51 (1.00–2.10) .52
 CSF/blood glucose ratio, median 
(IQR)
177 0.25 (0.16–0.33) 72 0.25 (0.19–0.34) 15 0.26 (0.18–0.36) 264 0.25 (0.16–0.33) .69
Ziehl-Neelsen smear positive 210 135 (64.3) 83 45 (54.2) 15 7 (46.7) 308 187 (60.7) .14
Xpert result positive 202 166 (82.2) 79 62 (78.5) 14 7 (50.0) 295 235 (79.7) .02
Duration of initial admission, d, 
median (IQR)
219 30 (23–38)w 86 31 (26–37) 16 30 (12–32) 321 30 (24–37) .46
Abbreviations: CSF, cerebrospinal fluid; GCS, Glasgow Coma Scale; HIV, human immunodeficiency virus; INH, isoniazid; IQR, interquartile range; MDR, multidrug resistant; MRC, British 
Medical Research Council; RIF, rifampicin; TB, tuberculosis; WBC, white blood cell.
aSummary statistics are frequency (%) for categorical and median (IQR) for continuous variables. P values are based on Fisher exact test (categorical data) or the Kruskal-Wallis test (con-
tinuous data).
bMRC denotes modified British Medical Research Council criteria. Grade 1 indicates a GCS score of 15 with no neurologic signs (baseline); grade 2, a score of 11–14 (or 15 with focal neu-
rologic signs); and grade 3, a score of ≤10.
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treatment with levofloxacin as part of second-line treatment, 
8  days after TBM treatment initiation. Three patients with 
MDR infection (detected by Xpert MTB/RIF) were treated with 
additional levofloxacin as part of second-line treatment with 
a median time to treatment of 10 days (IQR, 6–23 days). Two 
patients with MDR TBM received additional levofloxacin, but 
not second-line treatment, 1 in each arm (Figure 1).
Outcome
Overall, 90 of 322 (28.0%) patients died during follow-up: 27 
of 86 (31.4%) in the INH-R category, 11 of 16 (68.8%) in the 
MDR/RIF-R group, and 52 of 220 (23.6%) in the INH-S + RIF-S 
category (Figure  2A). Multivariable Cox regression identified 
HIV infection (HR, 2.60 [95% CI, 1.62–4.17], P < .001), disease 
severity grade (HR,  1.07 [95% CI, .62–1.84] for grade 2 vs 1; 
Figure 2. Time-to-event analysis by resistance category and human immunodeficiency virus (HIV) status. A, Kaplan-Meier (KM) estimates of survival during 9 months by 
resistance category. B, KM estimates of combined endpoint of time to new neurological event or death by resistance category. C, KM estimates of survival by resistance 
category of HIV-uninfected patients. D, KM estimates of survival by resistance category of HIV-infected patients. The light gray line represents patients with tuberculous 
meningitis (TBM) with no isoniazid (INH) or rifampicin (RIF) resistance. The darker gray line represents patients with TBM with INH resistance, but no RIF resistance. The black 
line represents patients with TBM with RIF resistance or multidrug resistance. Abbreviations: INH, isoniazid; MDR, multidrug resistance; RIF, rifampicin.
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HR, 4.53 [95% CI, 2.71–7.59] for grade 3 vs 1; overall P < .001) 
and MDR infection (HR, 5.91 [95% CI, 3.00–11.64], P < .001) as 
independent predictors of death, but not intensified treatment 
(HR, 0.92 [95% CI, .60–1.40], P = .70) or INH-R (HR, 1.30 [95% 
CI, .81–2.07], P = .28), consistent with previous predictors [14].
Of 322 patients, 154 (47.8%) patients met the combined 
endpoint of new neurological event and death: 64 (19.9%) neu-
rological events in survivors, 69 (21.4%) neurological events 
with subsequent death, and 21 (6.5%) deaths in patients with-
out a prior recorded neurological event. Adjusted Cox regres-
sion showed a significant effect of isoniazid resistance on the 
occurrence of any new neurological event or death combined 
(HR, 1.58 [95% CI, 1.11–2.23], P = .01) (Figure 2B).
Mortality in HIV-infected patients was increased (Figure 2C 
and D). Although mortality appeared higher in INH-R com-
pared to those without resistance in this subgroup, the com-
parison did not reach statistical significance (adjusted HR, 1.48 
[95% CI, .86–2.57], P = .16) (Figure 2D).
There was a nonsignificant trend toward worse disability at 
9  months in the INH-R category (cumulative OR, 1.44 [95% 
CI, .90–2.32], P = .13). Three of 5 survivors in the MDR/RIF-R 
group were left severely disabled (Table 2).
Seventy-eight INH-R isolates were available for molecular 
analysis: 70.5% had mutations in the KatG region (associated 
with high-level resistance), 19.2% had mutations in the inhA 
promoter region (associated with low-level resistance), and 
12.8% had no mutation identified. Survival by resistance muta-
tion is shown in Supplementary Figure 1. Resistance mutations 
were not associated with mortality by Cox regression (adjusted 
HR, 0.80 [95% CI, .31–2.06], P = .66).
Intensified Treatment
The overall effect of randomized intensified treatment on sur-
vival in INH-R and MDR/RIF-R is shown in Figure 3. In INH-R 
TBM, when stratified by disease severity and HIV status, the HR 
of death of intensified treatment vs standard treatment was 0.45 
(95% CI, .20–1.02, P = .06). For the combined outcome of new 
neurological event or death in INH-R patients, the stratified HR 
of intensified treatment was 0.60 (95% CI, .34–1.08, P  =  .09) 
(Figure  3C). Intensified treatment appeared to be predomi-
nantly beneficial in HIV-uninfected patients with isoniazid-re-
sistant infection (Figure  3D and 3E). Of the HIV-uninfected 
patients, 6 of 17 (35.3%) died in the standard treatment arm, 
compared with 1 of 22 (4.6%) in the intensified treatment arm 
(HR, 0.11 [95% CI, .01–.93], P = .04) (Figure 3D). In contrast, 
10 of 24 (41.7%) of HIV-infected patients with isoniazid resist-
ance died in the standard treatment arm, compared with 10 of 
23 (43.5%) in the intensified treatment arm (HR, 0.91 [95% CI, 
.38–2.18], P = .83) (Figure 3E).
Effect of Treatment Adjustment for INH-R
To extricate the effect of treatment adjustments on the over- 
or underestimation of the effect of early intensified treatment 
in INH-R TBM, we performed explorative analyses account-
ing for these late adjustments. Two different Cox regression 
models were created, including “fluoroquinolone use” as a 
time-dependent covariate, as initiation of treatment adjust-
ment is dependent on survival up to drug resistance detec-
tion. Within the INH-R group, 60 patients received treatment 
with at least a fluoroquinolone either as part of intensified 
treatment (n  =  45, early) or as targeted INH-R treatment 
(n  =  15, late), while 26 patients did not receive any intensi-
fied or adjusted treatment throughout 9 months of treatment. 
Of those receiving intensified treatment or adjustment with a 
fluoroquinolone, 15 of 60 (25.0%) died. In the standard treat-
ment group, with no treatment adjustment, 12 of 26 (46.1%) 
patients died. Cox regression showed a significant benefit 
of overall “fluoroquinolone use” on survival (HR, 0.38 [95% 
CI, .18–.80], P = .01), stratified by disease severity grade and 
HIV infection. A significant benefit of later adjustment only 
could not be established in this population (HR,  0.59 [95% 
CI, .18–1.91], P  =  .38) (Table  3). Furthermore, the second 
model showed a more pronounced effect on the rate of death 
for immediate treatment (HR, 0.34, affecting survival from the 
time of randomization onward) than of subsequent initiation 
(HR,  0.59, affecting survival only from the time of fluoro-
quinolone treatment initiation onward), suggesting that ear-
lier fluoroquinolone treatment is better.
Table 2. Disability Status at 9 Months by Resistance Category
Disability
No or Other Resistance  
(n = 220)
INH Resistant  
(n = 86)
RIF Resistant or MDR  
(n = 16)
Cumulative Odds Ratioa
(95% CI) P Value
Good 91 (41.4) 31 (36.0) 2 (12.5) INH: 1.44
Intermediate 53 (24.1) 17 (19.8) 0 (0) (.90–2.32) .13
Severe 20 (9.1) 11 (12.8) 3 (18.8) RIF MDR: 10.31
Death 52 (23.6) 27 (31.4) 11 (68.8) (3.39–31.36) <.001
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: CI, confidence interval; INH, isoniazid; MDR, multidrug resistance; RIF, rifampicin monoresistance.
aCumulative odds ratios for INH and RIF MDR (compared to no or other resistance) were obtained from a proportional odds logistical regression model with the resistance category as the 
main covariate and adjustment for human immunodeficiency virus status, tuberculous meningitis severity grade, and randomized treatment arm. 
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Figure 3. Time-to-event analysis by randomized treatment. A, Overall 9-month survival by randomized arm of 86 patients in the isoniazid-resistant, rifampicin-susceptible 
(INH-R) category. B, Overall 9-month survival by randomized treatment arm of 16 patients in the rifampicin multidrug resistance category. C, Time to new neurological event or 
death by randomized treatment of 86 patients in the INH-R category. D and E, Overall 9-month survival by randomized treatment of 39 human immunodeficiency virus (HIV)–
uninfected (D) and 47 HIV-infected (E) patients in the INH-R category. Cox regression was stratified by tuberculous meningitis severity grade and HIV status. Abbreviations: 
CI, confidence interval; HR, hazard ratio.
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Multidrug-Resistant TBM
In total, 15 patients had MDR and 1 patient had RIF-R TBM. 
The median time to death of MDR patients was 27 days (IQR, 
7–45 days). In the MDR/RIF-R group combined, 4 patients 
received second-line treatment according to the Vietnamese 
TB program guidelines (including an injectable aminoglyco-
side, kanamycin 20 mg/kg/day; a fluoroquinolone, levoflox-
acin 750 mg/day; pyrazinamide 25 mg/kg/day; and at least 2 
of ethionamide 15–20 g/kg/day, prothionamide 15–20 mg/kg/
day, cycloserine 15–20 mg/kg/day, or para-aminosalicylic acid 
8 g/day). Four patients receiving second-line treatment and 1 
patient on standard treatment survived 9 months. All other 
patients died, with a median time to death of 27 days (IQR, 
7–45 days). A summary of individual patient characteristics 
and treatment are given in Supplementary Table 2. The sam-
ple size was too small to detect potential efficacy of intensified 
treatment (HR, 0.63 [95% CI, .15–2.69], P = .54) (Figure 3B).
DISCUSSION
To date, no clinical trials have explored optimal treatment 
regimens for drug-resistant TBM. In our blinded randomized 
controlled trial of intensified antituberculosis treatment for 
Table  3. Effect of Intensified and Adjusted Treatment in Isoniazid-
Resistant, Rifampicin-Susceptible Tuberculous Meningitis
Treatment Hazard Ratio (95% CI) P Value
Fluoroquinolone use at any time pointa
 Intensified or adjusted treatment (Tdc) 0.38 (.18–.80) .01
 MRC grade
  1 1 (reference category)
  2 1.60 (.67–3.82) .29
  3 2.96 (1.11–7.89) .03
 HIV infection
  Uninfected 1 (reference category)
  Infected 2.93 (1.31–6.59) .01
Effect of later adjustmentsb
 Late adjustment regimen (Tdc) 0.59 (.18–1.91) .38
 Randomized arm
  Standard treatment 1 (reference category)
  Intensified treatment 0.34 (.15–.76) .01
 MRC grade
  1 1 (reference category)
  2 1.57 (.66–3.75) .31
  3 3.03 (1.14–8.08) .03
 HIV infection
  Uninfected 1 (reference category)
  Infected 2.82 (1.25–6.39) .01
Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; MRC, Medical 
Research Council; Tdc, time-dependent covariate.
aCox regression including treatment enrichment with a fluoroquinolone as a time-depen-
dent covariate, adjusted for tuberculous meningitis (TBM) severity grade (MRC grade) and 
HIV status. 
bCox regression including only late treatment adjustment as a time-dependent covariate, 
while treatment allocation is treated as a baseline covariate, corrected for TBM severity 
grade and HIV status. Eighty-six patients in the isoniazid-resistant, rifampicin-susceptible 
category were included in the analysis. 
TBM, intensified treatment led to reduction of mortality in 
INH-R infection. This finding is crucial, as isoniazid resist-
ance is increasingly prevalent and associated with worse out-
come. Improved treatment will impact mortality and morbidity 
of TBM. A  considerable proportion of baseline isolates were 
INH-R (26.7%), reflecting the high incidence of isoniazid-re-
sistant TB in Vietnam.
We performed a time-dependent Cox regression, to correct 
for relevant treatment adjustments made for drug-resistant 
infection. This showed that treatment benefit in INH-R was 
mainly generated by the early randomized intervention. We 
could not establish whether fluoroquinolones improved out-
comes from INH-R TBM when added later in treatment based 
on DST, but our findings underscore the necessity for improved 
early drug resistance detection. The use of rapid molecular 
testing of pulmonary TB by Xpert MTB/RIF has facilitated 
early diagnosis of rifampicin resistance and second-line treat-
ment initiation [22]. Xpert MTB/RIF has been recommended 
by the World Health Organization for direct use on CSF as the 
initial diagnostic test [21, 23]; however, isoniazid resistance 
cannot be detected by the current Xpert cartridge. The line-
probe assays, such as Genotype MTBDR (Hain Life-Science, 
Nehren, Germany), can detect both rifampicin and isoniazid 
resistance. Although the bacillary load in CSF is likely too low 
for direct use, these assays may be used on bacteria cultured 
from CSF samples, which should reduce time to resistance 
detection.
Eleven of 16 (68.8%) of those with MDR/RIF-R TBM died 
by 9 months. Of the 5 survivors, 4 received early second-line 
treatment, based on the results of Xpert MTB/RIF resistance 
testing. Early diagnosis of MDR TBM allows the instigation of 
second-line regimens, but few data are available to guide regi-
men tailoring.
The limitations of this study include the potential for missing 
patients with drug-resistant disease, due to the poor sensitivity 
of CSF culture. Only 39.4% (322/817) had a known drug resist-
ance profile; the impact of resistance on the remaining patients 
could not be assessed. Positive CSF culture may be linked to 
higher bacterial loads and worse outcomes, which may con-
found our findings. We had no minimum inhibitory concen-
trations or pharmacokinetic data for isoniazid. Higher-dose 
rifampicin and fluoroquinolone were given jointly as 1 inter-
vention; hence, it is impossible to tease the effect of both drugs 
apart. Higher doses of rifampicin have been associated with 
improved outcome in an Indonesian study [24]. In addition, the 
impact of later (nonrandomized) fluoroquinolone treatment 
on outcome is hard to assess given the small numbers and the 
potential for differences in disease severity and postrandomiza-
tion management to confound the analysis.
In conclusion, early intensified treatment increased survival 
in patients with INH-R TBM. Early detection of drug-resistant 
TBM is key to improving outcomes.
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Supplementary Data
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so questions or comments should be addressed to the corresponding author.
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